Lumexa Imaging initiated with an Overweight at Wells Fargo

Wells Fargo initiated coverage of Lumexa Imaging (LMRI) with an Overweight rating and $22 price target The company offers “attractive growth” in an end market with tailwinds due to lower cost of services and better experience for patients, the analyst tells investors in a research note. Wells says Lumexa is one of the largest providers of outpatient imaging services in the U.S. Imaging overall has solid demand and growth characteristics, the firm contends.